TherapeuticsMD Inc.

1.47+0.0050+0.34%Vol 2.61M1Y Perf -47.09%
Jul 7th, 2020 11:52 DELAYED
BID1.46 ASK1.47
Open1.44 Previous Close1.46
Pre-Market- After-Market1.46
 -1.46 -100.00%  - -%
Target Price
8.38 
Analyst Rating
Strong Buy 1.50
Potential %
475.95 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/78/93 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-42/49 
Growth Ranking
★★     44.53
Insiders Shares Cnt. % 3/6/12 mo.
100/-18/46 
Income Ranking
 —    -
Market Cap398.02M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
17.65 
Earnings Date
4th Aug 2020

Today's Price Range

1.411.49

52W Range

0.85304.32

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
16.80%
1 Month
23.73%
3 Months
64.04%
6 Months
-35.40%
1 Year
-47.09%
3 Years
-70.86%
5 Years
-82.15%
10 Years
-98.38%

TickerPriceChg.Chg.%
TXMD1.470.00500.34
AAPL378.084.23001.13
GOOG1 515.9820.28001.36
MSFT213.392.69001.28
XOM43.72-0.6700-1.51
WFC24.76-0.7300-2.86
JNJ143.520.54000.38
FB247.367.08002.95
GE6.80-0.2000-2.86
JPM92.75-2.2500-2.37
Financial StrengthValueIndustryS&P 500US Markets
3.10
3.40
0.96
22.31
-8.00
Leverage Ratio -14.80
ProfitabilityValueIndustryS&P 500US Markets
85.70
-296.70
-292.70
-504.70
-
RevenueValueIndustryS&P 500US Markets
51.87M
0.19
38.42
15.98
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.19-0.21-10.53
Q04 2019-0.20-0.195.00
Q03 2019-0.19-0.1331.58
Q02 2019-0.18-0.19-5.56
Q01 2019-0.17-0.165.88
Q04 2018-0.17-0.170.00
Q03 2018-0.22-0.1627.27
Q02 2018-0.12-0.15-25.00
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.1511.76Positive
9/2020 QR-0.1126.67Positive
12/2020 FY-0.596.35Positive
12/2021 FY-0.26-23.81Negative
Next Report Date4th Aug 2020
Estimated EPS Next Report-0.15
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume2.61M
Shares Outstanding271.68M
Trades Count5.13K
Dollar Volume3.75M
Avg. Volume4.77M
Avg. Weekly Volume4.19M
Avg. Monthly Volume4.82M
Avg. Quarterly Volume5.57M

TherapeuticsMD Inc. (NASDAQ: TXMD) stock closed at 1.46 per share at the end of the most recent trading day (a 5.04% change compared to the prior day closing price) with a volume of 4.46M shares and market capitalization of 398.02M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 241 people. TherapeuticsMD Inc. CEO is Robert G. Finizio.

The one-year performance of TherapeuticsMD Inc. stock is -47.09%, while year-to-date (YTD) performance is -39.67%. TXMD stock has a five-year performance of -82.15%. Its 52-week range is between 0.853 and 4.32, which gives TXMD stock a 52-week price range ratio of 17.65%

TherapeuticsMD Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 46.65, a price-to-sale (PS) ratio of 7.65, a price to cashflow ratio of 0.40, a PEG ratio of 2.32, a ROA of -85.89%, a ROC of -99.14% and a ROE of -2 499.18%. The company’s profit margin is -%, its EBITDA margin is -292.70%, and its revenue ttm is $51.87 Million , which makes it $0.19 revenue per share.

Of the last four earnings reports from TherapeuticsMD Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.15 for the next earnings report. TherapeuticsMD Inc.’s next earnings report date is 04th Aug 2020.

The consensus rating of Wall Street analysts for TherapeuticsMD Inc. is Strong Buy (1.5), with a target price of $8.38, which is +475.95% compared to the current price. The earnings rating for TherapeuticsMD Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

TherapeuticsMD Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

TherapeuticsMD Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.08, ATR14 : 0.12, CCI20 : 124.41, Chaikin Money Flow : -0.08, MACD : 0.03, Money Flow Index : 47.56, ROC : 21.67, RSI : 61.28, STOCH (14,3) : 100.00, STOCH RSI : 1.00, UO : 60.46, Williams %R : 0.00), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of TherapeuticsMD Inc. in the last 12-months were: Angus Charles Russell (Buy at a value of $126 600), Brian Bernick (Buy at a value of $127 700), Cooper C. Collins (Buy at a value of $107 300), Jane F. Barlow (Buy at a value of $9 998), John C.K. Milligan (Buy at a value of $274 700), John Milligan (Buy at a value of $274 700), Mitchell L. Krassan (Option Excercise at a value of $59 387), Mitchell L. Krassan (Sold 300 000 shares of value $676 920 ), Paul M. Bisaro (Buy at a value of $57 000), Robert G. Finizio (Buy at a value of $998 998), Tommy G. Thompson (Buy at a value of $25 031)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (75.00 %)
7 (87.50 %)
7 (87.50 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (25.00 %)
1 (12.50 %)
1 (12.50 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.25
Strong Buy
1.25

TherapeuticsMD Inc.

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

CEO: Robert G. Finizio

Teplephone: +1 561 961-1900

Address: 6800 Broken Sound Parkway NW, Boca Raton 33487, FL, USA

Number of employees: 241

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

40%60%

Bearish Bullish

41%59%

Bearish Bullish

43%57%

News

Stocktwits